Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF1 | P18846 | 12/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 12/20 | 0.62 |
| ▸ | XPO1 | O14980 | 4/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8398360 | 0.88 | NFKB1 (0.56) | ATF1NFKB1XPO1JUNNFKB2 | |
| SCHEMBL8398500 | 0.85 | NFKB1 (0.53) | ATF1NFKB1XPO1JUNNFKB2 | |
| SCHEMBL1549128 | 0.84 | KDM4E (0.71) | ATF1NFKB1XPO1JUNNFKB2 | |
| SCHEMBL30617280 | 0.84 | KDM4E (0.71) | ATF1NFKB1XPO1JUNNFKB2 | |
| SCHEMBL4592101 | 0.83 | MAPT (0.57) | ATF1NFKB1XPO1JUNNFKB2 | |
| SCHEMBL8518174 | 0.82 | NFKB1 (0.62) | ATF1NFKB1XPO1JUNNFKB2 | |
| SCHEMBL1759818 | 0.81 | MAPT (0.53) | ATF1NFKB1JUNNFKB2RELA | |
| SCHEMBL15038313 | 0.81 | KDM4E (0.72) | ATF1NFKB1JUNNFKB2RELA | |
| Water SCHEMBL4593114 | 0.81 | MAPT (0.56) | ATF1NFKB1XPO1JUNNFKB2 | |
| SCHEMBL1860264 | 0.81 | ATF1 (0.58) | ATF1NFKB1XPO1JUNNFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | disclosed |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-11 | — | — | US | disclosed |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-13 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-1049682-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | Versicor, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6140351-A | FOR TREATING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1040108-A1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000018759-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999032477-A1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999011612-A2 | SUBSTITUTED CYCLIC COMPOUNDS AND MIXTURES COMPRISING SAME | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1998005961-A1 | COMPOUNDS HAVING A PLURALITY OF NITROGENOUS SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | ZC3HAV1, ZC3HAV1L, IFNAR1 | ATF1 3055/4885NFKB1 2121/4885XPO1 2951/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | ATF1 2577/4885NFKB1 2837/4885XPO1 1965/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | ATF1 2577/4885NFKB1 2837/4885XPO1 1965/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | ATF1 2920/4885NFKB1 774/4885XPO1 2632/4885 |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | ATF1 2577/4885NFKB1 2837/4885XPO1 1965/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | ATF1 2920/4885NFKB1 774/4885XPO1 2632/4885 |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | ATF1 2577/4885NFKB1 2837/4885XPO1 1965/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | ATF1 2577/4885NFKB1 2837/4885XPO1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.